Elżbieta Mikiciuk-Olasik

Elżbieta Mikiciuk-Olasik

Auto-generated profile, based on publicly available information

Elżbieta Mikiciuk-Olasik

Department of Pharmaceutical Chemistry and Drug Analysis, Medical University, Łódź, Poland

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2020 in Bioconjugate Chemistry
Verified
Journal Article
Open access
PKPaweł Kręcisz
Paweł Kręcisz
KCKamila Czarnecka
Kamila Czarnecka
LKLeszek Królicki
Leszek Królicki
EMElżbieta Mikiciuk-Olasik
Elżbieta Mikiciuk-Olasik
PSPaweł Szymanski
Paweł Szymanski
Radiolabeled peptides are a relatively new, very specific radiotracer group, which is still expanding. This group is very diverse in terms of peptide size. It contains very small structures containing several amino acids and whole antibodies. Moreover, radiolabeled peptides are diverse in terms of the binding aim and therapeutic or diagnostic applications. The majority of this class of radiotracers is utilized in oncology, where the same structure can be used in therapy and diagnostic imaging by varying the radionuclide. In this study, we collected new reports of radiolabeled peptide applications in diagnosis and therapy in oncology and other fields of medicine. Radiolabeled peptides are also increasingly being used in rheumatology, cardiac imaging, or neurology. The studies collected in this review concern new therapeutic and diagnostic procedures in humans and new structures tested on animals. We also performed an analysis of clinical trials, which concerns application of radiolabeled peptides and antibodies that were reported in the clinicaltrials.gov database between 2008 and 2018.

13 April 2004 in Archiv der Pharmazie
Verified
Journal Article
Closed access
PDF file
EMElżbieta Mikiciuk‐Olasik
Elżbieta Mikiciuk‐Olasik
KBKatarzyna Baszczak‐Światkiewiz
Katarzyna Baszczak‐Światkiewiz
EŻElżbieta Żurek
Elżbieta Żurek
UKUrszula Krajewska
Urszula Krajewska
MRMarek Różalski
Marek Różalski
TBTadeusz J. Bartczak
Tadeusz J. Bartczak

17 July 2019 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
MPMaria Podsiedlik
Maria Podsiedlik
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka
EMElżbieta Mikiciuk-Olasik
Elżbieta Mikiciuk-Olasik
JSJoanna Sikora
Joanna Sikora
The aim of this review was to examine the relationship between the occurrence of central nervous system (CNS) diseases, the medicines used in their treatment and the blood coagulation process. The paper mainly focuses on the effects of antidepressant and antipsychotic drugs. Special attention has been paid to the influence of drugs on platelets, the vascular endothelium, plasma coagulation and fibrinolysis, regarding coagulation.

1 January 2000
Verified
Journal Article
Closed access
EME Mikiciuk-Olasik
E Mikiciuk-Olasik
EZE Zurek
E Zurek
RMR Mikołajczak
R Mikołajczak
EZE Zakrzewska
E Zakrzewska
KBK Błaszczak-Swiatkiewicz
K Błaszczak-Swiatkiewicz